Peptone Ltd.

Peptone Ltd. specializes in enhancing protein characterization through advanced computational techniques, providing effective solutions for the biotechnology and pharmaceutical industries. Founded in 2016, Peptone Ltd. is based in London, UK, and focuses on innovative protein characterization solutions.

The company was established to help researchers overcome challenges in protein production and analysis, facilitating drug development. Kamil Tamiola is the CEO and founder, with previous ventures contributing to his expertise. Peptone has completed 2 deals, with the most recent one on April 8, 2022, during its Series A funding round, raising GBP 31. 85 million, valuing the company at GBP 69.

62 million post-money. The funding was led by investors including F-Prime Capital and Bessemer Venture Partners, among others. Peptone develops innovative solutions to enhance protein characterization for the biotechnology and pharmaceutical sectors. Its proprietary platform utilizes advanced computational techniques to optimize protein production and analysis, addressing challenges such as precise protein folding and functionality.

The technology serves a diverse clientele, including academic institutions, research laboratories, and biopharmaceutical companies across North America, Europe, and Asia, providing tools that enhance the efficiency and accuracy of protein studies. Peptone generates revenue through direct sales and subscription-based access to its technology platform. It partners with research institutions and biopharmaceutical firms, offering tiered subscription plans for varying access levels and additional bespoke services. Revenue also comes from licensing proprietary technology and collaborative projects, with its flagship product being a key element of its revenue stream.

Following the Series A funding round on April 8, 2022, Peptone Ltd. plans to utilize the GBP 31. 85 million raised to establish a research facility in Bellinzona, Switzerland. The company aims to expand its geographic presence and bring innovative products to market in the biotechnology sector.

Specific timelines for product launches and market expansions have not been disclosed, but the new facility is expected to enhance research capabilities and facilitate growth into new markets.